 |
 |
 |
Journal articles
Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment
Abstract : Objective To investigate the cutaneous tolerance of febuxostat in gouty patients with skin intolerance to allopurinol. Methods We identified all gouty patients who had sequentially received allopurinol and febuxostat in the rheumatology departments of 4 university hospitals in France and collected data from hospital files using a predefined protocol. Patients who had not visited the prescribing physician during at least 2 months after febuxostat prescription were excluded. The odds ratio (OR) for skin reaction to febuxostat in patients with a cutaneous reaction to allopurinol versus no reaction was calculated. For estimating the 95% confidence interval (95% CI), we used the usual Wald method and a bootstrap method. Results In total, 113 gouty patients had sequentially received allopurinol and febuxostat; 12 did not visit the prescribing physician after febuxostat prescription and were excluded. Among 101 patients (86 males, mean age 61 ± 13.9 years), 2/22 (9.1%) with a history of cutaneous reactions to allopurinol showed skin reactions to febuxostat. Two of 79 patients (2.5%) without a skin reaction to allopurinol showed skin intolerance to febuxostat. The ORs were not statistically significant with the usual Wald method (3.85 [95% CI 0.51–29.04]) or bootstrap method (3.86 [95% CI 0.80–18.74]). Conclusion The risk of skin reaction with febuxostat seems moderately increased in patients with a history of cutaneous adverse events with allopurinol. This moderate increase does not support the cross-reactivity of the two drugs
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01255828
Contributor : Laurent Jonchère <>
Submitted on : Thursday, January 14, 2016 - 9:58:03 AM
Last modification on : Thursday, January 14, 2021 - 11:23:50 AM
Contributor : Laurent Jonchère <>
Submitted on : Thursday, January 14, 2016 - 9:58:03 AM
Last modification on : Thursday, January 14, 2021 - 11:23:50 AM